• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Phase III trial uses innovative delivery system to treat DME

Article

Alimera Sciences Inc. and Control Delivery Systems Inc. (CDS) began a phase III clinical trial to study patients with diabetic macular edema (DME) treated using the Medidur implant to deliver fluocinolone acetonide.

The masked, randomized, multicenter study will follow 900 patients in the United States and Europe for 36 months. The Medidur implant, injected through a needle during an in-office procedure, is expected to provide sustained delivery of fluocinolone acetonide to the back of the eye for up to 3 years, according to Alimera Sciences.

"Advanced therapies require innovative methods of delivery, and Medidur fits that model," said Dan Myers, president and chief executive officer of Alimera Sciences, Alpharetta, GA. "The Alimera Sciences team is delighted to reach this critical product development milestone with CDS at such a stage of our company's progression. We anticipate that Medidur technology will allow eye-care professionals to provide their DME patients with an effective and long-lasting therapeutic treatment."

Related Videos
© 2024 MJH Life Sciences

All rights reserved.